English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Schizophrenia is a chronic mental disorder that affects more than 21 million people worldwide, and changes the way people think, feel, and act.1,2 The incidence of schizophrenia is 2 to 5 cases per 1000 population per year, and its prevalence is 1% of the world’s population. In Indonesia, especially in North Sulawesi Province, the prevalence of schizophrenia is about 0.8 per 1000 populations.3 Pharmacotherapy by using antipsychotics is the first-line choice in schizophrenia therapy.4,5 Meta-analysis studies showed that atypical-antipsychotics like risperidone is more effective than typical-antipsychotic like haloperidol.6 But there is a risk of side effects for either haloperidol or risperidone, thus in the practice, those antipsychotics were combined trihexyphenidyl.4 As a chronic disease, schizophrenia is associated with a decrease in productivity and a low quality of life.7 Various clinical factors related to the life quality of schizophrenic patients have been reported. A cross-sectional study stated that psychopathological symptoms have a stronger correlation with a community function.8 Correlation between atypical antipsychotic with cognitive function also revealed there is a significant improvement.9 Even though atypical antipsychotic (risperidone) has been recognized as the first-line choice for schizophrenia therapy in the real clinical practice, the typical antipsychotic is still given to schizophrenia patients (Fujimaki 2012),10 similar to the practice in Prof. Ratumbuysang . ABSTRACT

international journal of current research and review

The Use of Risperidone-combination and Haloperidol-combination in Schizophrenia Patients; a Cost Utility Analysis in Psychiatric Hospital of Prof. V. L. Ratumbuysang